BioNTech, which developed one of the world’s most commonly used COVID-19 vaccines along with Pfizer, is attempting to gain approval soon for vaccinating children between the ages of 5 and 11 across the world, top executives with the firm announced Friday.
“Already over the next few weeks we will file the results of our trial in 5- to 11-year-olds with regulators across the world and will request approval of the vaccine in this age group, also here in Europe,” Chief Medical Officer Oezlem Tuereci told German publication Der Spiegel…
Views: